LexDanaLexDanabeta
Inventor

WOUTER KORVER

Inventor
US

Overview

6→
Patents
2022–2025
Patent span
Human necessities
Primary field (CPC A)

Patents· 6 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
C07KPeptides32%
A61KPreparations for medical, dental or toiletry purposes26%
C12NMicroorganisms or enzymes11%
PatentTitleYear
12,312,411Anti-CD38 binding domains202512,209,138Anti-CD38 antibodies202511,912,766Anti-Siglec-7 antibodies having reduced effector function202411,773,162Anti-Siglec-7 antibodies for the treatment of cancer202311,434,304Anti-CD38 antibodies202211,414,496Anti-CD38 binding domains2022

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2022–2025Patents assigned to TAKEDA PHARMACEUTICALS CO (4)· patent assignee history
2022Patents assigned to MILLENNIUM PHARM INC (1)· patent assignee history
2022–2025Based in US· patent location history
2023–2024Patents assigned to ALLAKOS INC (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
TAKEDA PHARMACEUTICALS CO42022–2025
ALLAKOS INC22023–2024
MILLENNIUM PHARM INC12022
Locations
LocationPatentsSpan
US62022–2025